Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1964 1
1966 2
1967 1
1970 2
1971 13
1972 16
1973 12
1974 17
1975 19
1976 6
1977 9
1978 10
1979 11
1980 7
1981 11
1982 11
1983 11
1984 11
1985 7
1986 5
1987 7
1988 4
1989 4
1990 10
1991 3
1992 8
1993 8
1994 17
1995 11
1996 15
1997 11
1998 17
1999 20
2000 16
2001 17
2002 15
2003 14
2004 17
2005 16
2006 14
2007 12
2008 25
2009 29
2010 34
2011 53
2012 57
2013 41
2014 35
2015 35
2016 32
2017 44
2018 41
2019 39
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

842 results
Results by year
Filters applied: . Clear all
Page 1
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Zhang Z, Deng W, Wu Q, Sun L. Zhang Z, et al. Immunotherapy. 2019 Mar;11(4):321-333. doi: 10.2217/imt-2018-0113. Epub 2019 Jan 11. Immunotherapy. 2019. PMID: 30630365 Review.
Tofacitinib has been studied extensively in patients with rheumatoid arthritis and has been shown to be effective and generally safe. East Asian countries have a high background rate of tuberculosis (TB) and hepatitis B virus (HBV) infection and the risk of r …
Tofacitinib has been studied extensively in patients with rheumatoid arthritis and has been shown to be effective and generally safe. …
Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizokami M, Hata A. Fujita M, et al. J Viral Hepat. 2018 Nov;25(11):1312-1320. doi: 10.1111/jvh.12933. Epub 2018 Jun 13. J Viral Hepat. 2018. PMID: 29770539
This study aimed to determine the incidence and risk factors for hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) undergoing immunosuppressive therapy. ...Laboratory tests of the hepatitis B surface antigen, anti- …
This study aimed to determine the incidence and risk factors for hepatitis B virus (HBV) reactivation in patients with rheumat …
Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapy.
Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S. Intongkam S, et al. J Clin Rheumatol. 2019 Dec;25(8):329-334. doi: 10.1097/RHU.0000000000000877. J Clin Rheumatol. 2019. PMID: 31764493
OBJECTIVES: The aims of this study were to assess efficacy and safety of the hepatitis B vaccination in rheumatoid arthritis (RA) patients receiving conventional and/or biological disease-modifying antirheumatic drugs (DMARDs). ...Aging and rituximab use were …
OBJECTIVES: The aims of this study were to assess efficacy and safety of the hepatitis B vaccination in rheumatoid arthriti
Management of hepatitis B and C infections in rheumatologic disease.
Cheah JT, Faragon JJ, Marks KM. Cheah JT, et al. Best Pract Res Clin Rheumatol. 2018 Dec;32(6):848-868. doi: 10.1016/j.berh.2019.04.001. Best Pract Res Clin Rheumatol. 2018. PMID: 31427059 Review.
Hepatitis B and C viruses present dual considerations in rheumatic disease as both etiologic factors and important comorbidities that must be assessed and addressed. This review summarizes the link between hepatitis B and arthritis and polyarter
Hepatitis B and C viruses present dual considerations in rheumatic disease as both etiologic factors and important comorbiditi
Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T. Watanabe T, et al. Int J Rheum Dis. 2019 Apr;22(4):574-582. doi: 10.1111/1756-185X.13401. Epub 2018 Oct 18. Int J Rheum Dis. 2019. PMID: 30338649 Clinical Trial.
AIM: To identify the incidence and risk factors for hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with resolved HBV receiving biological disease-modifying antirheumatic drugs (bDMARDs). METHOD: Rheumatoid arthritis patients …
AIM: To identify the incidence and risk factors for hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) p …
Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW. Ahn SS, et al. Yonsei Med J. 2018 May;59(3):452-456. doi: 10.3349/ymj.2018.59.3.452. Yonsei Med J. 2018. PMID: 29611409 Free PMC article.
To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negati …
To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reac …
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.
Chen YM, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, Hsieh TY. Chen YM, et al. Ann Rheum Dis. 2018 May;77(5):780-782. doi: 10.1136/annrheumdis-2017-211322. Epub 2017 Jun 29. Ann Rheum Dis. 2018. PMID: 28663308 No abstract available.
Rheumatoid Factors in Hepatitis B and C Infections: Connecting Viruses, Autoimmunity, and Cancer.
Moll J, Isailovic N, De Santis M, Selmi C. Moll J, et al. Isr Med Assoc J. 2019 Jul;21(7):480-486. Isr Med Assoc J. 2019. PMID: 31507125 Free article. Review.
Mixed cryoglobulinemia and lymphoproliferative disease are prime examples of the deleterious effects of rheumatoid factor-B cell activity, possibly associated with hepatitis B and C. ...We provide a comprehensive overview of the known connections between h
Mixed cryoglobulinemia and lymphoproliferative disease are prime examples of the deleterious effects of rheumatoid factor-B cell acti …
Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review.
Mazzaro C, Dal Maso L, Visentini M, Gitto S, Andreone P, Toffolutti F, Gattei V. Mazzaro C, et al. J Intern Med. 2019 Sep;286(3):290-298. doi: 10.1111/joim.12913. Epub 2019 May 24. J Intern Med. 2019. PMID: 31124596 Review.
Cryoglobulinemic vasculitis (CV) can develop in 1.2-4% of hepatitis B virus (HBV)-infected patients. HBV infection affects about 350 million people worldwide. It can progress from acute or fulminant hepatitis to chronic hepatitis, cirrhosis or hepatoce …
Cryoglobulinemic vasculitis (CV) can develop in 1.2-4% of hepatitis B virus (HBV)-infected patients. HBV infection affects abo …
Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis.
Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, Galli M. Sebastiani M, et al. Joint Bone Spine. 2017 Oct;84(5):525-530. doi: 10.1016/j.jbspin.2017.05.013. Epub 2017 May 18. Joint Bone Spine. 2017. PMID: 28529116 Review.
OBJECTIVES: Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). ...Patients with active hepatitis B should undergo antiviral treatment before starting immunosuppressive t …
OBJECTIVES: Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid …
842 results
Jump to page
Feedback